ET-700 — Topline data
H2 2026
Topline study results are expected in the second half of 2026, and if positive, would lead to a pivotal clinical study in early 2027.Source filing
ETON biotech catalysts & pipeline
ETON PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
KHINDIVI (hydrocortisone) — NDA/BLA submission
Q3 2026
Eton intends to file the supplement in the third quarter of 2026, which could provide for a potential approval in the second quarter of 2027.Source filing
AMGLIDIA® — NDA/BLA submission
Late 2026
The Company plans to initiate a bioavailability study for the product later this month and remains on track to submit an NDA by the end of 2026, allowing for potential approval and launch in 2027.Source filing
KHINDIVI (hydrocortisone) — Regulatory decision
Q2 2027
Eton intends to file the supplement in the third quarter of 2026, which could provide for a potential approval in the second quarter of 2027.Source filing
ASN-001 — NDA/BLA submission
H2 2027
The Company plans to initiate a bioavailability study and anticipates a New Drug Application ("NDA") submission upon the study's completion in the second half of 2027.Source filing